What is Seer?
Founded in 2017, Seer operates at the intersection of biotechnology and data science. The company specializes in developing innovative tools that enable researchers to capture high-resolution proteomic data, a critical frontier in modern medicine. By providing unprecedented access to the proteome, Seer empowers the scientific community to identify novel biomarkers and therapeutic targets that were previously inaccessible. This technological edge has positioned the firm as a key player in the precision medicine landscape, attracting a diverse syndicate of high-profile backers who recognize the transformative potential of its molecular analysis capabilities.
How much funding has Seer raised?
Seer has raised a total of $479.5M across 7 funding rounds:
Series A
$6M
Series B
$36M
Series C
$17.5M
Series D
$55M
Multiple Rounds
$365M
Series A (2017): $6M with participation from Maverick Ventures
Series B (2018): $36M led by Invus and Maverick Ventures
Series C (2019): $17.5M supported by AJU IB INVESTMENT, Maverick Ventures, Invus, and Wing Companies
Series D (2019): $55M featuring aMoon
Other Financing Round (2020): $55M backed by Fidelity Investments Inc., T. Rowe Price Associates, aMoon, Maverick Ventures, HBM Healthcare Investments AG, and Invus
Share Placement (2020): $135M with participation from T. Rowe Price, aMoon Fund, SoftBank, and Fidelity
Stock Issuance/Offering (2020): $175M led by Undisclosed
Key Investors in Seer
T. Rowe Price
A global asset management organization providing comprehensive investment solutions and financial services through active management, fundamental research, and long-term strategic perspectives.
Fidelity
A diversified financial services firm offering investment, wealth management, and retirement planning solutions supported by extensive technological resources and market expertise.
Maverick Ventures
A venture capital firm focused on supporting technology start-ups with capital and operational guidance, particularly within the AI, healthcare, and cybersecurity sectors.
What's next for Seer?
Following its recent major strategic investment, Seer is well-positioned to scale its commercial operations and expand the reach of its proteomic platform. The company's trajectory suggests a focus on deepening its research partnerships and enhancing its product suite to meet the growing demand for high-throughput molecular diagnostics. As Seer transitions into its next phase of growth, the focus will likely shift toward broader clinical adoption and the integration of its insights into drug discovery pipelines, further cementing its role as an essential infrastructure provider for the next generation of life sciences innovation.
See full Seer company page
